Scroll for more
news Dec 6, 2016

BenevolentBio’s artificial intelligence could discover a better treatment for ALS

Professor Jackie Hunter today took to the stage at this year’s Disrupt London 2016. In this article – a summary of Professor Hunter’s live Q&A at the event – she discusses machine learning and its application in the search for better treatments for amyotrophic lateral sclerosis (ALS). Professor Hunter’s interview also talks about BenevolentBio’s use of AI technology particularly focusing on how it seeks to ‘augment’ not replace scientists specialising in drug discovery.

A summary of the Q&A and a full video of the discussion produced by TechCrunch are available via this link.